As much as I want to say that market got it wrong, I have to accept the fact that the market didn't take the DKD results in a positive way.
Is there anything that will change that perception, absolutely. Another major pharma player doing P3 will be a huge boost of confidence.
On Covid, I am also skeptical but hoping for the best.
Regardless, even with one FSGS indication and specially given no competition, current MC is too low relative to other biotechs in similar development phase.
As much as I want to say that market got it wrong, I have to...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $211.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $246.4K | 658.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 262775 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 32276 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |